Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the effects of SMS 201-995 (SMS), a somatostatin analog, and tamoxifen, an antagonist of estrogenic actions, on the growth of human pancreatic cancers (SKI and PGER) in vivo. Male nude mice were inoculated with either SKI or PGER by passage of tumor chunks (3 mm2) to the scapular region. Mice from each tumor group were randomly allocated to one of four treatment groups: group 1, control group; group 2, SMS (100 micrograms/kg t.i.d.); group 3, tamoxifen (10 mg/kg three times a week); and group 4, SMS (100 micrograms/kg t.i.d.) + tamoxifen (10 mg/kg three times a week). The somatostatin analog, SMS, given alone or as a combined regimen with tamoxifen, significantly reduced (a) the rate of growth of SKI, and (b) DNA, RNA, and protein content of the tumors. On the other hand, in the case of PGER tumors, none of the treatment regimens significantly influenced the growth of PGER in vivo. Despite showing no significant effects during the study, PGER tumors in mice receiving tamoxifen alone had significantly lower total DNA, RNA, and protein contents compared to control tumors; this was reversed on combined treatment with SMS. None of the growth parameters of PGER was effected by SMS alone. We conclude that, in the case of SKI, SMS with or without tamoxifen was effective as a growth inhibitory agent, whereas in the case of PGER, tamoxifen alone was effective. This finding suggests that independent pathways mediate the growth-inhibitory effects of tamoxifen and SMS, and that different pancreatic cancers may respond to the two agents differently, some with inhibition, some not.
 ...
PMID:Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. 215 57

Transgenic mice bearing a fusion gene consisting of rat elastase I 5' flanking DNA fused to the early-coding (T-antigen) region of the SV40 genome (ELSV mice) develop carcinomas of the acinar cells of the exocrine pancreas. Histopathological examination of pancreatic tissue from 79 such animals revealed that, in addition to acinar cell neoplasms, ELSV mice develop two distinct lesions of the islets of Langerhans. By the age of 26 weeks, 36% of the mice had developed insulinomas. Starting at 8 weeks of age, the mice also developed D (somatostatin)-cell hyperplasia, which began at the periphery of the islets but which in advanced cases resulted in nearly complete replacement of other islet cell types by D-cells. By 26 weeks of age, 85% of the mice examined demonstrated the D-cell abnormality. Both the insulinomas and D-cell lesions were negative by immunohistochemistry for T-antigen, which was, however, demonstrated in acinar cell neoplasms using a monoclonal antibody against a C-terminal T-antigen epitope. Insulinomas have been described in other SV40 transgenic mice, particularly when the SV40 enhancer is not included in the transgene, suggesting that the presence of native SV40 enhancer may ordinarily suppress the expression of T-antigen in pancreatic beta-cells. The somatostatin-cell lesion is unique to the ELSV model; it may be neoplastic or represent a response to the growth and neoplastic changes occurring simultaneously in the exocrine pancreas.
 ...
PMID:Hyperplasia and tumors of the islets of Langerhans in mice bearing an elastase I-SV40 T-antigen fusion gene. 216 83

The nuclear DNA content of 17 pancreatic neuroendocrine tumors was measured from paraffin-embedded tissue with flow cytometry. The tumors were classified by immunostaining with antisera for synaptophysin, insulin, gastrin, glucagon, pancreatic polypeptide, somatostatin, and vasoactive intestinal polypeptide. Eight (47%) of the 17 tumors were aneuploid, and two (12%) were multiploid (had two aneuploid stemlines of cells). Seven of the eight insulinomas, one of the four gastrinomas, and two of the four nonspecified neuroendocrine tumors had an abnormal nuclear DNA content. The DNA indices of the aneuploid and multiploid cases ranged from 1.13 to 1.93, and three cases had a DNA index greater than 1.50. During the follow-up for up to 16 years (mean, 7 years), one patient with diploid nonspecified tumor died of the disease, another patient with a multiploid gastrinoma had metastatic disease develop, and a third patient with a multiploid nonspecified tumor was alive with the disease. The authors conclude that many neuroendocrine tumors of the pancreas have an abnormal nuclear DNA content as measured by DNA flow cytometry. DNA multiploid pancreatic neuroendocrine tumors may be associated with a less favorable clinical course, but this needs to be confirmed in additional studies.
 ...
PMID:DNA ploidy in pancreatic neuroendocrine tumors. 234 35

We examined the effect of vasoactive intestinal peptide, substance P, and somatostatin on concanavalin A (1 microgram/ml)-induced lymphocyte proliferation and immunoglobulin (IgA, IgM, and IgG) synthesis by cells from spleens, Peyer's patches, and mesenteric lymph nodes. These neuropeptides (10(-7) to 10(-12) M) modulated immune responses in a dose-dependent manner. For a comparative study, neuropeptides were used at 10(-8) M concentration. Both vasoactive intestinal peptide and somatostatin significantly decreased DNA synthesis (30 to 50%), whereas substance P increased synthesis (40%) in lymphocytes from all organs tested. IgA synthesis was significantly altered by all of the neuropeptides tested, whereas IgM synthesis was less affected and IgG synthesis was virtually unchanged. Somatostatin inhibited IgA (20 to 50%) and IgM (10 to 30%) synthesis in lymphocytes from all three organs. Substance P increased IgA synthesis in mesenteric lymph nodes (50%), spleens (70%), and Peyer's patches (300%). It also increased IgM synthesis in Peyer's patches (20%) and spleens (30%), but was without effect on IgM synthesis in mesenteric lymph nodes. Vasoactive intestinal peptide increased the IgA response in mesenteric lymph nodes (20%) and spleens (30%), but inhibited IgA synthesis in lymphocytes from Peyer's patches (60%). Interestingly, in Peyer's patches, IgM synthesis was increased by vasoactive intestinal peptide (80%), whereas it was unchanged in mesenteric lymph nodes and spleen. Thus, not only did these neuropeptides have different effects on the production of different immunoglobulin isotypes, but their effect was also organ-specific. Because neuropeptides which are abundant in the intestine can modulate IgA and other immunoglobulin synthesis in vitro, they may play a significant regulatory role in mucosal immune responses in vivo.
 ...
PMID:Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. 241 14

We investigated the impact of chronically administered synthetic cyclic somatostatin-14 on the nude mouse. Four groups of seven animals each received intraperitoneal injections twice daily for 14 days with diluent or 5, 50, or 500 mcg/kg somatostatin in hydrolyzed gelatin. Overall health and body weight were unaffected by this treatment. Among the seven organs examined at necropsy, kidney alone showed a dose-related gain in weight with increasing somatostatin dose. Renal RNA content also increased in response to somatostatin treatment, but liver DNA content and small bowel DNA content and protein content decreased. This work indicates that somatostatin affects metabolism of gastrointestinal tissues and provides evidence that renal growth can be regulated by somatostatin. Whether similar effects occur at a physiological somatostatin level is unknown, but the current findings suggest new therapeutic possibilities for this hormone.
 ...
PMID:Effect of chronically administered somatostatin on the nude mouse. 242 41

To understand the hormonal regulation of steady-state growth hormone (GH) mRNA levels, we investigated the interaction between somatostatin and agents known to increase intracellular cAMP activity on GH mRNA, GH synthesis, cell content of GH, and GH release in primary cultures of rat anterior pituitary cells. We simultaneously studied the modulation of the steady-state of pro-opiomelanocortin (POMC) mRNA levels by cAMP. In four independent experiments, a 48-hr exposure to 0.3 mM 3-isobutyl-1-methylxanthine (IBMX) or 3 mM 8-bromoadenosine 3',5'-cyclic monophosphate (8Br-cAMP) increased GH mRNA levels from 70 to 170% and from 70 to 150% above control (p less than 0.001), respectively. Parallel increases in GH release accompanied by a corresponding decrease in the intracellular content of GH were also obtained. Following a 48-hr incubation with 100 nM somatostatin alone, no change in GH mRNA levels was observed whereas GH release was inhibited by 90%, GH cell content doubled, and GH synthesis decreased by 40%. Surprisingly, somatostatin potentiated the enhancing effect of 8Br-cAMP on GH mRNA levels. In the same cell preparation, a 48-hr exposure to IBMX or 8Br-cAMP stimulated adrenocorticotropin release by 9.4- and 18.0-fold, respectively, and increased POMC mRNA levels by 2.4- and 2.3-fold (p less than 0.001), respectively. No change in beta-actin mRNA was observed after these treatments. These data indicate that increased intracellular cAMP concentrations increase the steady-state level of GH mRNA.(ABSTRACT TRUNCATED AT 250 WORDS)
DNA 1986 Aug
PMID:Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture. 242 92

This study examines the effects of somatocrinin (GRF) and somatostatin antiserum (ASS) alone, and in combination, on liver growth. Twenty-four-day-old rats were injected s.c. twice daily for 14 days with either saline or GRF (4 and 20 micrograms X kg-1). ASS was given i.p. every 2 days. GRF alone had no effect on liver weight, but produced hyperplasia and increased RNA content. ASS alone had no effect on RNA, DNA, and protein contents. Potentiation of the effects of GRF by ASS was observed on liver weight and DNA content. Indeed, this combined treatment resulted in increased organ weight and hyperplasia at an intermediary level of GRF. These data indicate that a strong interaction exists between GRF and ASS on the control of liver growth, possibly through the release of growth hormone (GH).
 ...
PMID:Effect of somatocrinin and a somatostatin antiserum on liver growth in the rat. 243 9

This study examines the effects of somatocrinin (GRF) and somatostatin antiserum (ASS), jointly and separately on gastric and duodenal growth. 24-day-old rats received twice daily SC injections of saline or GRF (4 and 20 micrograms X kg-1) for 14 days. ASS was given IP every 2 days. Alone, GRF increased gastric fundus weight concomitantly with DNA, RNA and protein contents producing hyperplasia and hypertrophy within this gland. Alone, ASS increased RNA and protein cellular concentrations. Joint ASS and GRF treatment stabilized the weight and protein content of the fundus, while reducing RNA contents as well as RNA and protein concentrations. GRF alone caused significant increments in duodenal weight and protein content suggesting cellular hypertrophy. Growth hormone, gastrin, cholecystokinin and secretin may be considered as putative mediators of these trophic effects.
 ...
PMID:Effect of somatocrinin and a somatostatin antiserum on duodenal and gastric growth in the rat. 243 13

The current study examines the effects of somatocrinin (GRF) and somatostatin antiserum (ASS) alone and in combination on pancreatic growth. Twenty-four-day-old rats were injected daily s.c. at 10:00 and 16:30 h for 14 days with either saline or GRF (4 and 20 micrograms X kg-1). ASS was given i.p. every other day. Pancreatic weights and DNA, RNA, protein, amylase, and chymotrypsin total contents and concentrations were evaluated at the end of treatment. GRF alone was associated with significant decreases in pancreatic weight and contents of protein, amylase, and chymotrypsin but with significant increases in total DNA content indicating pancreatic atrophy and hyperplasia. ASS alone has a slight effect on DNA content but potentiates GRF given at the dose of 4 micrograms X kg-1. Even though ASS reduced protein and enzyme contents, it prevented the large decreases observed with increasing doses of GRF. These data present for the first time effects of GRF and ASS on pancreatic growth and describe a strong interaction between the two products. It is yet too early to determine how these two substances work on the pancreatic acinar cells, but hypotheses on their possible mode of action are proposed.
 ...
PMID:Effect of somatocrinin with or without a somatostatin antiserum on pancreatic growth. 243 58

This study was undertaken to determine the influence of somatostatin on the growth of gastric, duodenal, and pancreatic tissue in rats placed on liquid diet. In the first part of the study animals were fed an elemental liquid diet for 10 days and then killed, and the growth of the oxyntic gland area of the stomach, 2 cm segments of duodenum and pancreatic tissue was determined. Feeding an elemental diet caused a decrease in organ weight, nucleic acid contents and serum gastrin level. Subsequent addition of pentagastrin prevented this reduction in organ weight and RNA and DNA contents while somatostatin failed to affect the decrease in growth parameters or serum gastrin level in tests with or without addition of pentagastrin. In a second part of the study, sham operated and antrectomised rats were used. Antrectomy caused a significant decrease in serum gastrin concentration and resulted in a significant reduction in the weight and RNA and DNA contents of the tissue tested. As in liquid diet, subsequent administration of pentagastrin prevented the reduction in the growth parameters both in tests with and without somatostatin. These results suggest that somatostatin inhibits the growth of the gastroduodenal mucosa by a mechanism involving, at least in part, the suppression of gastrin release.
 ...
PMID:Effect of somatostatin on the growth of gastrointestinal mucosa and pancreas in rats. Role of endogenous gastrin. 244 62


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>